The global health burden of infection -associated cancers in the year 2002

被引:2207
作者
Parkin, Donald Maxwell
机构
[1] Univ Oxford, Clin Trials Serv Unit, Oxford OX3 7LF, England
[2] Univ Oxford, Epidemiol Studies Unit, Oxford OX3 7LF, England
关键词
infection; cancer; attributable fraction; estimates;
D O I
10.1002/ijc.21731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several infectious agents are considered to be causes of cancer in humans. The fraction of the different types of cancer, and of all cancers worldwide and in different regions, has been estimated using several methods; primarily by reviewing the evidence for the strength of the association (relative risk) and the prevalence of infection in different world areas. The estimated total of infection-attributable cancer in the year 2002 is 1.9 million cases, or 17.8% of the global cancer burden. The principal agents are the bacterium Helicobacter pylori (5.5% of all cancer), the human papilloma viruses (5.2%), the hepatitis B and C viruses (4.9%), Epstein-Barr virus (1%), human immunodeficiency virus (HIV) together with the human herpes virus 8 (0.9%). Relatively less important causes or cancer are the schistosomes (0.1%), human T-cell lymphotropic virus type 1 (0.03%) and the liver flukes (0.02%). There would be 26.3% fewer cancers in developing countries (1.5 million cases per year) and 7.7% in developed countries (390,000 cases) if these infectious diseases were prevented. The attributable fraction at the specific sites varies from 100% of cervix cancers attributable to the papilloma viruses to a tiny proportion (0.4%) of liver cancers (worldwide) caused by liver flukes. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:3030 / 3044
页数:15
相关论文
共 171 条
  • [1] Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa
    Ablashi, D
    Chatlynne, L
    Cooper, H
    Thomas, D
    Yadav, M
    Norhanom, AW
    Chandana, AK
    Churdboonchart, V
    Kulpradist, SAR
    Patnaik, M
    Liegmann, K
    Masood, R
    Reitz, M
    Cleghorn, F
    Manns, A
    Levine, PH
    Rabkin, C
    Biggar, R
    Jensen, F
    Gill, P
    Jack, N
    Edwards, J
    Whitman, J
    Boshoff, C
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (05) : 893 - 897
  • [2] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [3] [Anonymous], IARC MON EV CARC RIS
  • [4] [Anonymous], IARC MON EV CARC RIS
  • [5] [Anonymous], 2003, IARC Scientific publications
  • [6] [Anonymous], GLOBOCAN 2002 CANC I
  • [7] Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823
  • [8] Arisawa K, 2000, INT J CANCER, V85, P319, DOI 10.1002/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO
  • [9] 2-B
  • [10] ARMSTRONG AA, 1992, LEUKEMIA, V6, P869